NVX-CoV2373-话题@MedSci

#NVX-CoV2373#

9篇内容 | 1372人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1318204, encodeId=bfdf131820442, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=COVID-19疫苗NVX-CoV2373在青少年中的有效率接近80%, objectType=article, longId=295608, objectId=86fe2956086d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86fe2956086d, replyNumber=0, likeNumber=60, createdTime=2022-02-16, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86fe2956086d, moduleTitle=COVID-19疫苗NVX-CoV2373在青少年中的有效率接近80%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86fe2956086d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318203, encodeId=1f97131820323, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=Lancet Respir Med：同时接种流感疫苗是否影响NVX-CoV2373疫苗的安全性与免疫原性？, objectType=article, longId=220967, objectId=dd2c22096e13, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd2c22096e13, replyNumber=0, likeNumber=64, createdTime=2021-11-26, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd2c22096e13, moduleTitle=Lancet Respir Med：同时接种流感疫苗是否影响NVX-CoV2373疫苗的安全性与免疫原性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd2c22096e13)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318202, encodeId=c0a3131820253, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=NEJM：NVX-CoV2373疫苗对新冠肺炎南非变异株的预防效果超过50%, objectType=article, longId=210907, objectId=487721090e2e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=487721090e2e, replyNumber=0, likeNumber=85, createdTime=2021-05-08, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=487721090e2e, moduleTitle=NEJM：NVX-CoV2373疫苗对新冠肺炎南非变异株的预防效果超过50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=487721090e2e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318201, encodeId=a3c1131820180, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=英国、美国、欧盟和加拿大开始对COVID-19疫苗NVX-CoV2373进行滚动审查, objectType=article, longId=206930, objectId=6f5c20693047, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f5c20693047, replyNumber=0, likeNumber=84, createdTime=2021-02-10, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f5c20693047, moduleTitle=英国、美国、欧盟和加拿大开始对COVID-19疫苗NVX-CoV2373进行滚动审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f5c20693047)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318200, encodeId=b12913182002e, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=NEJM：NVX-CoV2373疫苗表现出良好的安全性及免疫效果, objectType=article, longId=204392, objectId=17ae20439271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17ae20439271, replyNumber=0, likeNumber=77, createdTime=2020-12-12, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17ae20439271, moduleTitle=NEJM：NVX-CoV2373疫苗表现出良好的安全性及免疫效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17ae20439271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318199, encodeId=135d131819988, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, objectType=article, longId=201324, objectId=3539201324d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3539201324d6, replyNumber=0, likeNumber=86, createdTime=2020-09-30, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3539201324d6, moduleTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3539201324d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318197, encodeId=b1b6131819e8b, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=NEJM：新冠病毒疫苗NVX-CoV2373的1-2期临床试验结果, objectType=article, longId=200243, objectId=97ee20024318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97ee20024318, replyNumber=0, likeNumber=92, createdTime=2020-09-05, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97ee20024318, moduleTitle=NEJM：新冠病毒疫苗NVX-CoV2373的1-2期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97ee20024318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318198, encodeId=40741318198fa, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人, objectType=article, longId=200219, objectId=a20d20021917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a20d20021917, replyNumber=0, likeNumber=58, createdTime=2020-09-05, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a20d20021917, moduleTitle=NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a20d20021917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318196, encodeId=ffeb1318196a5, content=<a href='/topic/show?id=c0e1131645d' target=_blank style='color:#2F92EE;'>#NVX-CoV2373#</a>, objectTitle=Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验, objectType=article, longId=194739, objectId=c5e8194e39ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e8194e39ed, replyNumber=0, likeNumber=74, createdTime=2020-05-28, rootId=0, userName=szhvet, userId=ec37461, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e8194e39ed, moduleTitle=Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e8194e39ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NVX-CoV2373

2020-05-29

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

COVID-19疫苗NVX-CoV2373在青少年中的有效率接近80%

2022-02-16

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

Lancet Respir Med：同时接种流感疫苗是否影响NVX-CoV2373疫苗的安全性与免疫原性？

2021-11-26

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

NEJM：NVX-CoV2373疫苗对新冠肺炎南非变异株的预防效果超过50%

2021-05-08

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

英国、美国、欧盟和加拿大开始对COVID-19疫苗NVX-CoV2373进行滚动审查

2021-02-10

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

NEJM：NVX-CoV2373疫苗表现出良好的安全性及免疫效果

2020-12-12

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验

2020-09-30

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

NEJM：新冠病毒疫苗NVX-CoV2373的1-2期临床试验结果

2020-09-05

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

NEJM：NVX-CoV2373新冠肺炎疫苗I-II期临床数据喜人

2020-09-05

szhvet (审核中...)

前往app查看评论内容

#NVX-CoV2373#

Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验

2020-05-28

科室
- - 订阅+
  - 更多科室
工具
服务